Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Abstract The 2021 WHO Classification of Thoracic Tumours was published earlier this year,
with classification of lung tumors being one of the chapters. The principles remain those of …

Introduction Recent studies have identified subtypes of small cell lung carcinoma (SCLC)
defined by the RNA expression of ASCL1, NEUROD1, POU2F3, and YAP1 transcriptional …

Small cell lung cancer (SCLC) is characterized by morphologic, epigenetic and
transcriptomic heterogeneity. Subtypes based upon predominant transcription factor …

Small cell lung cancer (SCLC) is a neuroendocrine tumor treated clinically as a single
disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based …

Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more
than two decades without clinical progress, the addition of programmed cell death protein 1 …

The neuroendocrine carcinoma of the gastrointestinal system (GIS-NEC) is a rare but highly
malignant neoplasm. We analyzed 115 cases using whole-genome/exome sequencing …

Immune checkpoint blockade (ICB) benefits only a small subset of patients with small cell
lung cancer (SCLC), yet the mechanisms driving benefit are poorly understood. To identify …

Neuroendocrine neoplasms (NENs) comprise well-differentiated neuroendocrine tumors
(NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Treatment options for …

We performed comprehensive proteogenomic characterization of small cell lung cancer
(SCLC) using paired tumors and adjacent lung tissues from 112 treatment-naive patients …